Universal Beteiligungs und Servicegesellschaft mbH Buys 44,607 Shares of Denali Therapeutics Inc. $DNLI

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 170.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,830 shares of the company’s stock after buying an additional 44,607 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Denali Therapeutics were worth $1,169,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Headlands Technologies LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at about $26,000. Johnson Financial Group Inc. bought a new stake in shares of Denali Therapeutics during the third quarter valued at about $29,000. State of Wyoming bought a new stake in shares of Denali Therapeutics during the second quarter valued at about $29,000. Quarry LP bought a new stake in shares of Denali Therapeutics during the third quarter valued at about $64,000. Finally, Assetmark Inc. increased its position in shares of Denali Therapeutics by 31.8% during the fourth quarter. Assetmark Inc. now owns 5,187 shares of the company’s stock valued at $86,000 after buying an additional 1,250 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Stock Down 2.2%

DNLI stock opened at $18.30 on Friday. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $20.26 and its 200 day moving average is $18.77. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -6.16 and a beta of 1.00. Denali Therapeutics Inc. has a 1-year low of $12.58 and a 1-year high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter in the prior year, the firm earned ($0.67) earnings per share. Sell-side analysts predict that Denali Therapeutics Inc. will post -2.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DNLI shares. Leerink Partners decreased their price target on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Stifel Nicolaus upped their price target on Denali Therapeutics from $34.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wall Street Zen cut Denali Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 25th. Robert W. Baird upped their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, Wolfe Research assumed coverage on shares of Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $35.00.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.